Sluggish February Home Sales 3/23/26 - Your Money Minute

Summary2 min read

Episode Overview

Episode Title: Sluggish February Home Sales 3/23/26
Podcast: Your Money Minute (CNBC)
Host: Jessica Ettinger
Air Date: March 23, 2026
Duration: ~1 minute (excluding ads)

This episode covers the latest data on the U.S. housing market for February 2026, highlighting trends in home sales, prices, and buyer demographics. CNBC’s Jessica Ettinger, referencing insights from Diana Olek, discusses the implications for the spring home buying season, including home price trends, market supply, and the increasing presence of investors.

Key Discussion Points and Insights

1. Home Sales Rebound—But Still Sluggish

[00:05] Existing home sales in February showed a "small rebound" compared to January.
However, the number of homes sold is "still below the number of homes that sold the same month last year," suggesting ongoing weakness as the traditionally busy spring homebuying season begins.

2. Inventory and Prices

There remains "not a ton of homes out there for sale," keeping upward pressure on prices.
Median price: "$398,000, an increase of 0.3% year over year."
The market's tight supply continues to sustain high prices despite slower sales.

3. Selling Pace Slows

[00:25] On-market time has stretched:
- "It continues to take longer to sell a home—47 days, up from 42 a year ago."
Fewer quick sales may indicate buyers are becoming more cautious, or supply and affordability issues are impacting activity.

4. Who Is Buying?

[00:32] There's a notable uptick in first-time buyers:
- "34% of buyers were first timers, an increase from 31% a year ago."

5. Investors’ Impact

More attention is being paid to the share of purchased homes going to investors—companies or individuals who "plan to flip or just rent out the property," not to live in themselves.
[00:42] "16% of sales were to investors—a change from a year ago." (Note: specific year-over-year change not detailed)

6. Where to Learn More

The episode ends by referencing more market data and details available at CNBC.com.

Notable Quotes & Memorable Moments

Jessica Ettinger [00:05]:

“A small rebound, but the number was still below the number of homes that sold the same month last year. And that hints at a sluggish start to the spring home buying season.”
Diana Olek (via Ettinger) [00:18]:

“The median price of a home sold in February? $398,000, an increase of 0.3% year over year.”
Jessica Ettinger [00:23]:

“It continues to take longer to sell a home—47 days, up from 42 a year ago.”

Segment Timestamps

00:00-00:50 – Main market update: sales numbers, pricing, time on market, first-time and investor buyers
00:50-01:12 – Episode wrap-up and reference to CNBC.com for more resources

Summary Tone and Style

Direct, concise, and data-driven—delivering key insights quickly for financially curious listeners.

For further information on home buying and selling trends, including the latest data, listeners are directed to CNBC.com.

Loading summary

Transcript2 lines

[00:00]
A
With a CNBC you Money minute. I'm Jessica Edinger. More existing homes sold in February than in January. A small rebound, but the number was still below the number of homes that sold the same month last year. And that hints at a sluggish start to the spring home buying season. Without a ton of homes out there for sale, prices stayed high. Too tight supply is still pressuring prices. The median price of a home sold in February? $398,000, an increase of 0.3% year over year. That's see NBC's Diana Olek. She adds that homes sat on the market longer last month. It continues to take longer to sell a home 47 days, up from 42 a year ago. 34% of buyers were first timers, an increase from 31% a year ago. One detail people are paying a lot of attention to now how many existing homes were sold to investors, not other people planning to move in, but to companies that plan to flip or just rent out the property. 16% of sales were to investors. Change from a year ago. More on buying and selling a home and more Data are@cnbc.com I'm Jessica Ettinger, CNBC.
[01:13]
B
Snoring, gasping during sleep? Feeling fatigued? Wake up to Zepbound Tirzepatide, the first and only FDA approved prescription medicine for moderate to severe obstructive sleep apnea in adults with obesity. Zeb Bound is an injectable prescription medicine that may help adults with moderate to severe obstructive sleep apnea and obesity to improve their osa. Zebound should be used with a reduced calorie diet and increased physical activity. Zepbound is Approved as a 2.5, 5, 7.5, 10, 12.5 or 15mg injection. Zepbound contains Tirzepatide and should not be used with other Tirzepatide containing products or any GLP1 receptor agonist medicines. It is not known if Zepbound is safe and effective for use in children. Do not share needles or pins or reuse needles. Don't take Zeb Bound if allergic to it or if you or someone in your family had medullary thyroid cancer or multiple endocrine neoplasia syndrome type 2. Tell your doctor if you get a lump or swelling in your neck. Stop Zepbound and call your doctor if you have severe stomach pain or serious allergic reaction. Severe side effects may include inflamed pancreas or gallbladder problems. Tell your doctor if you experience vision changes, depression or suicidal thoughts before scheduled procedures with anesthesia. If you're nursing pregnant, plan to be or taking birth control pills. Taking zetbound with a sulfonylurea or insulin may cause low blood sugar. Side effects include nausea, diarrhea and vomiting, which can cause dehydration and worsen kidney problems. Talk to your doctor, call 1-800-545-5979 or visit zepbound.lilly.com Zepbound and its delivery device base and QuickPen are registered trademarks owned or licen by eli Lilly Co. Its subsidiaries or affiliates.